Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Skin Cancer: Recent Advances for Personalized Treatment
share announcement

Skin Cancer: Recent Advances for Personalized Treatment

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (25 February 2022) | Viewed by 14245

Special Issue Editor

Dr. Elisabetta Palazzo

E-Mail Website
Guest Editor
DermoLab, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy
Interests: skin cancer; squamous cell carcinoma; psoriasis; epidermal homeostasis; keratinocyte stem cells; epidermal differentiation; skin inflammation; mouse models; zebrafish models; in vitro skin 3D model; skin tumor spheroids; next-generation sequencing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Skin cancer affects millions of people worldwide and its incidence is showing a rapid increase every year, making it a public health concern. Both sun exposure and other pathological conditions may interfere with the onset of lesions by also affecting unexposed areas of the skin.

Recently, with the advent of a number of sophisticated technologies, we are witnessing an increasingly in-depth analysis of all those factors that can increase our predisposition to the development of melanoma or non-melanoma skin cancer as well as defining those individual characteristics that improve diagnosis and treatment. And, we all know that the early detection of skin cancer gives the greatest chance for a successful cure.

In this Special Issue of the Journal of Personalized Medicine, manuscripts concerning neoplastic cell-specific markers or molecular profiles aimed at defining novel diagnostic tools promoting personalized therapies are welcome.

Dr. Elisabetta Palazzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Squamous cell carcinoma
  • Basal cell carcinoma
  • Melanoma
  • Skin cancer
  • Skin inflammation
  • Hyperplasia
  • Gene expression profiling
  • Molecular target therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 1778 KiB  
Review
Xeroderma Pigmentosum: General Aspects and Management
by Monica Piccione, Anna Belloni Fortina, Giulia Ferri, Gloria Andolina, Lorenzo Beretta, Andrea Cividini, Emanuele De Marni, Francesca Caroppo, Ugo Citernesi and Rosa Di Liddo
J. Pers. Med. 2021, 11(11), 1146; https://doi.org/10.3390/jpm11111146 - 4 Nov 2021
Cited by 11 | Viewed by 10173
Abstract
Xeroderma Pigmentosum (XP) is a rare genetic syndrome with a defective DNA nucleotide excision repair. It is characterized by (i) an extreme sensitivity to ultraviolet (UV)-induced damages in the skin and eyes; (ii) high risk to develop multiple skin tumours; and (iii) neurologic [...] Read more.
Xeroderma Pigmentosum (XP) is a rare genetic syndrome with a defective DNA nucleotide excision repair. It is characterized by (i) an extreme sensitivity to ultraviolet (UV)-induced damages in the skin and eyes; (ii) high risk to develop multiple skin tumours; and (iii) neurologic alterations in the most severe form. To date, the management of XP patients consists of (i) early diagnosis; (ii) a long-life protection from ultraviolet radiation, including avoidance of unnecessary UV exposure, wearing UV blocking clothing, and use of topical sunscreens; and (iii) surgical resections of skin cancers. No curative treatment is available at present. Thus, in the last decade, in order to prevent or delay the progression of the clinical signs of XP, numerous strategies have been proposed and tested, in some cases, with adverse effects. The present review provides an overview of the molecular mechanisms featuring the development of XP and highlights both advantages and disadvantages of the clinical approaches developed throughout the years. The intention of the authors is to sensitize scientists to the crucial aspects of the pathology that could be differently targeted. In this context, the exploration of the process underlining the conception of liposomal nanocarriers is reported to focus the attention on the potentialities of liposomal technology to optimize the administration of chemoprotective agents in XP patients. Full article
(This article belongs to the Special Issue Skin Cancer: Recent Advances for Personalized Treatment)
►▼ Show Figures

Figure 1

16 pages, 351 KiB  
Review
Emerging Minimally Invasive Technologies for the Detection of Skin Cancer
by Joon Min Jung, Ji Young Cho, Woo Jin Lee, Sung Eun Chang, Mi Woo Lee and Chong Hyun Won
J. Pers. Med. 2021, 11(10), 951; https://doi.org/10.3390/jpm11100951 - 24 Sep 2021
Cited by 11 | Viewed by 3160
Abstract
With the increasing incidence of skin cancer, many noninvasive technologies to detect its presence have been developed. This review focuses on reflectance confocal microscopy (RCM), optical coherence tomography (OCT), high-frequency ultrasound (HFUS), electrical impedance spectroscopy (EIS), pigmented lesion assay (PLA), and Raman spectroscopy [...] Read more.
With the increasing incidence of skin cancer, many noninvasive technologies to detect its presence have been developed. This review focuses on reflectance confocal microscopy (RCM), optical coherence tomography (OCT), high-frequency ultrasound (HFUS), electrical impedance spectroscopy (EIS), pigmented lesion assay (PLA), and Raman spectroscopy (RS) and discusses the basic principle, clinical applications, advantages, and disadvantages of each technology. RCM provides high cellular resolution and has high sensitivity and specificity for the diagnosis of skin cancer. OCT provides lower resolution than RCM, although its evaluable depth is deeper than that of RCM. RCM and OCT may be useful in reducing the number of unnecessary biopsies, evaluating the tumor margin, and monitoring treatment response. HFUS can be mainly used to delineate tumor depths or margins and monitor the treatment response. EIS provides high sensitivity but low specificity for the diagnosis of skin malignancies. PLA, which is based on the genetic information of lesions, is applicable for the detection of melanoma with high sensitivity and moderate-to-high specificity. RS showed high accuracy for the diagnosis of skin cancer, although more clinical studies are required. Advances in these technologies for the diagnosis of skin cancer can lead to the realization of optimized and individualized treatments. Full article
(This article belongs to the Special Issue Skin Cancer: Recent Advances for Personalized Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop